SCHEMBL4789373

SCHEMBL4789373

COC(=O)CC1CCN(C(=O)CNCCNc2ccccn2)Cc2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.48
KDM4E B2RXH2 2/20 0.41
HTT P42858 1/20 0.41
ITGB3 P05106 8/20 0.41
ITGAV P06756 8/20 0.41
ITGA2B P08514 6/20 0.41
ITGB5 P18084 4/20 0.41
ITGB1 P05556 1/20 0.41
NOS2 P35228 1/20 0.40
GRIN2B Q13224 1/20 0.39
ADRA1A P35348 1/20 0.39
ALDH1A1 P00352 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KCNH2 Q12809 1/20 0.36
HTR1A P08908 1/20 0.36
HTR1D P28221 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4761828 0.90 DPP4 (0.50) DPP4KDM4EHTTITGB3ITGAV
SCHEMBL4760965 0.86 NAMPT (0.45) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4760436 0.85 ITGB3 (0.51) DPP4KDM4EHTTITGB3ITGAV
SCHEMBL4762157 0.85 ITGB3 (0.51) DPP4KDM4EHTTITGB3ITGAV
SCHEMBL4790307 0.84 ITGB3 (0.44) DPP4ITGB3ITGAVITGA2BITGB5
SCHEMBL4714941 0.82 GRIN2B (0.39) DPP4ITGB3ITGAVITGA2BITGB5
SCHEMBL4791396 0.79 ITGB3 (0.44) DPP4ITGB3ITGAVITGA2BITGB5
SCHEMBL4791386 0.79 ITGB3 (0.51) DPP4ITGB3ITGAVITGA2BITGB5
SCHEMBL4790911 0.78 NAMPT (0.49) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4718481 0.78 PTGDR2 (0.38) KDM4EALDH1A1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed